2023-10-20T02:57:45+03:00[Europe/Moscow] en true <p>Neoadjuvant </p>, <p>Adjuvant </p>, <p>square root of: Ht(cm) x Wt (kg)/3600</p>, <p>CTCAE</p>, <p>b</p>, <p>a</p>, <p>cisplatin + pemetrexed x 4 cycles</p>, <p>cisplatin + gemcitabine x 4 cycles OR cisplatin + docetaxel x 4 cycles</p>, <p>AUC x (GFR + 25)</p>, <p>(140-age) x (kg)/72 x serum creatine * 0.85 (if female) </p>, <p>atezolizumab(every 2-4 weeks for 1 year) or pembrolizumab (every 3-6 weeks for 1 year) </p>, <p>osimertinib 80mg; QD for 3 years</p>, <p>endocrinopathy </p>, <p>hold dose of immunotherapy &amp; resume once symptoms resolve</p>, <p>prednisone until ADE resolved then slowly taper; hold immunotherapy</p>, <p>steroids + consider infliximab; discontinue immunotherapy </p>, <p>surgery, neo/adjuvant chemo, chemoradiation, consolidation therapy</p>, <p>a</p>, <p>b</p>, <p>d</p>, <p>asians </p>, <p>d</p>, <p>platinum doublet + nivolumab x 3 cycles </p>, <p>platinum doublet x 4 cycles</p>, <p>platinum doublet + radiation </p>, <p>durvalumab up to 1 year </p>, <p>adenocarcinoma, large cell </p>, <p>PD-L1&gt; 1%, ALK rearrangement, EGFR mutation </p>, <p>surgery</p>, <p>surgery + adjuvant chemotherapy ( if nodal involvement); radiation</p>, <p>after 2 or more cycles of chemoradiation + good response</p>, <p>cure; prevent progression </p>, <p>not curable; slow disease progression </p>, <p>PD-L1, EGFR, ALK</p>, <p>PD-L1</p>, <p>EGFR positive + Stage IV</p>, <p>PD-L1 &gt;= 50%</p>, <p>ECOG: 0-1= platinum analog + pemetrexed + pembrolizumab </p>, <p>ECOG: 0-1= carboplatin + abraxane + pembrolizumab</p>, <p>platinum doublet </p> flashcards
Therapeutics of Lung Cancer (NSCLC)

Therapeutics of Lung Cancer (NSCLC)

Customize
collection saved
Share
Long Term Learning Spaced Repetition
Add to Long Term Learning Desk
Fast learning Repeat this set of flashcards
Preview Test Spell
Play
Match
Review

  • Neoadjuvant

    -chemotherapy given PRIOR to surgical resection

  • Adjuvant

    -chemotherapy given after surgical resection

  • square root of: Ht(cm) x Wt (kg)/3600

    BSA formula?

  • CTCAE

    -is a standardized system for grading and reporting the severity of adverse effects (side effects or toxicities) of medical treatments

  • b

    Informs us of therapeutic efficacy.

    a) Prognostic Biomarker

    b) Predictive Biomarker

  • a

    Informs us of patient survival independent of treatment received.

    a) Prognostic Biomarker

    b) Predictive Biomarker

  • cisplatin + pemetrexed x 4 cycles

    What is the chemotherapy treatment for Nonsquamous?

  • cisplatin + gemcitabine x 4 cycles OR cisplatin + docetaxel x 4 cycles

    What is the chemotherapy treatment for Squamous? (2)

  • AUC x (GFR + 25)

    Carboplatin dosing?

  • (140-age) x (kg)/72 x serum creatine * 0.85 (if female)

    Cockcroft-Gault Equation?

  • atezolizumab(every 2-4 weeks for 1 year) or pembrolizumab (every 3-6 weeks for 1 year)

    Which treatments do we use if PD-L1> 1% or ALK rearrangements are present? (2)

  • osimertinib 80mg; QD for 3 years

    Which treatments do we use if EGFR mutation is present?

  • endocrinopathy

    If ________ develops, it will not go away.

  • hold dose of immunotherapy & resume once symptoms resolve

    If a low-grade AE (1) occurs, what treatment options do we have? *IMMUNOTHERAPY

  • prednisone until ADE resolved then slowly taper; hold immunotherapy

    If moderate grade (2-3) occurs, what treatment options do we have?

    *IMMUNOTHERAPY

  • steroids + consider infliximab; discontinue immunotherapy

    If severe grade (4) occurs, what treatment options do we have?

    *IMMUNOTHERAPY

  • surgery, neo/adjuvant chemo, chemoradiation, consolidation therapy

    What are the treatment options for Stage: III ? (4)

  • a

    EGFR positive.

    a) osimertinib

    b) immunotherapy

    c) sotorasib

    d) systemic chemotherapy

  • b

    PD-L1>1%

    a) osimertinib

    b) immunotherapy

    c) sotorasib

    d) systemic chemotherapy

  • d

    No mutations are present.

    a) osimertinib

    b) immunotherapy

    c) sotorasib

    d) systemic chemotherapy

  • asians

    EGFR mutations are most common in ________.

  • d

    When is mandatory for patients to have molecular testing done?

    a) Stage I NSCLC

    b) Stage II NSCLC

    c) Stage III NSCLC

    d) Stage IV NSCLC

  • platinum doublet + nivolumab x 3 cycles

    What is our Neoadjuvant chemo regimen? *STAGE 3

  • platinum doublet x 4 cycles

    What is our Adjuvant Chemotherapy regimen? *STAGE 3

  • platinum doublet + radiation

    What is our Chemoradiation regimen? *STAGE 3

  • durvalumab up to 1 year

    What is our Consolidation therapy? *STAGE 3

  • adenocarcinoma, large cell

    What are our Non-Squamous Cancers? (2)

  • PD-L1> 1%, ALK rearrangement, EGFR mutation

    When is Adjuvant targeted therapy indicated? (3)

  • surgery

    What is the treatment for Stage 1?

  • surgery + adjuvant chemotherapy ( if nodal involvement); radiation

    What is the treatment for Stage 2?

    What if there are positive margins?

  • after 2 or more cycles of chemoradiation + good response

    When is consolidation therapy indicated? (2)

  • cure; prevent progression

    What is the goal of Stage 3?

  • not curable; slow disease progression

    What is the goal of Stage 4?

  • PD-L1, EGFR, ALK

    What tests are used for Non-Squamous cell: Stage 4? (3)

  • PD-L1

    Which test is used for Squamous cell: Stage 4?

  • EGFR positive + Stage IV

    When can Osimertinib be started 1st line?

  • PD-L1 >= 50%

    When can immunotherapy be used as monotherapy?

  • ECOG: 0-1= platinum analog + pemetrexed + pembrolizumab

    Treatment for Stage IV: Non-Squamous +NO Mutation?

  • ECOG: 0-1= carboplatin + abraxane + pembrolizumab

    Treatment for Stage IV: Squamous cell + No mutation?

  • platinum doublet

    ECOG: 2 will always have what treatment?